Ind-Swift Laboratories Ltd Quarterly Results
Q3 FY25-26 Results Summary
Revenue
The revenue stands at ₹150.85 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 1.17 per cent from ₹152.64 crore. This corresponds to a year-on-year *(YoY) growth of 17.12 per cent.
Operating Profit
Operating Profit stands at ₹-1.68 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 214.29 per cent from ₹1.47 crore. This corresponds to a year-on-year *(YoY) growth of 77.20 per cent.
PBDT
PBDT stands at ₹25.25 crore, reflecting a quarter-on-quarter *(QoQ) increase of 46.21 per cent from ₹17.27 crore. This corresponds to a year-on-year *(YoY) growth of 3,422.37 per cent.
Profit Before Tax
Profit Before Tax stands at ₹16.41 crore, reflecting a quarter-on-quarter *(QoQ) increase of 59.48 per cent from ₹10.29 crore. This corresponds to a year-on-year *(YoY) growth of 349.77 per cent.
Net Profit
Net Profit stands at ₹9.54 crore, reflecting a quarter-on-quarter *(QoQ) increase of 19.40 per cent from ₹7.99 crore. This represents a 273.77 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Ind-Swift Laboratories Ltd Earnings
- YOY
- QOQ
Ind-Swift Laboratories Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Ind-Swift Laboratories Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Ind-Swift Laboratories Ltd Financial Reports
Ind-Swift Laboratories Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Ind-Swift Labs. | -1.57% | 2.20% | -0.85% | -1.61% | 40.29% | 69.58% |
| Jagsonpal Pharma | 1.06% | -0.05% | 0.17% | 28.34% | -4.26% | -13.71% |
| Fredun Pharma | -1.13% | -6.26% | 13.03% | 52.01% | 22.27% | 207.48% |
| Shukra Pharma. | 2.71% | -3.14% | -3.34% | -28.31% | -26.27% | 107.61% |
| Wanbury | 4.72% | 5.60% | 16.67% | 19.21% | 17.67% | 6.29% |
| Themis Medicare | 6.62% | 12.84% | 21.74% | 38.51% | 7.53% | -18.51% |
| Bajaj Healthcare | 1.27% | 0.33% | -5.32% | -5.74% | -28.75% | -43.80% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : N R Munjal
ED / Joint MD / Promoter : Himanshu Jain
Executive Director : Rishav Mehta
Executive Director : Sahil Munjal
Independent Non Executive Women Director : Neerja Chathley
Independent Non Exe. Director : Rajinder Kumar Gupta
Independent Non Exe. Director : SUBODH GUPTA
Independent Non Exe. Director : Prabhat Khurana
VP / Company Secretary / Compliance Officer : Pradeep Verma